Prospective, Observational Trial Evaluating Xeomin (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States.

Trial Profile

Prospective, Observational Trial Evaluating Xeomin (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States.

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Blepharospasm; Torticollis
  • Focus Therapeutic Use
  • Acronyms XCiDaBLE
  • Sponsors Merz Pharma
  • Most Recent Events

    • 21 Apr 2016 Results comparing response patterns from ANCHOR-CD, CD-PROBE and XCiDaBLE studies, presented at the 68th Annual Meeting of the American Academy of Neurology
    • 18 Jun 2015 Results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
    • 25 Apr 2015 Final results from the cervical dystonia cohort (n=369) presented at the 67th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top